Meta-Analysis of Tyrosine Kinase Inhibitors for Advanced Gastric Cancer

A 2026 meta-analysis of 10 randomized controlled trials involving 1,810 patients with advanced or metastatic gastric cancer. The dataset synthesizes hazard ratios for overall and progression-free survival, risk ratios for response rates, and adverse event data from trials comparing TKI-containing regimens to non-TKI regimens. It was authored by Yongshan Li following a systematic review of literature up to March 1, 2026.

Use Cases

• Pool hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) to quantify the survival benefit of TKI regimens.
• Analyze risk ratios (RRs) for objective response rate (ORR) and disease control rate (DCR) to assess treatment efficacy beyond survival endpoints.
• Compare subgroup analysis results, such as the differential efficacy between TKI monotherapy and combination with chemotherapy, to inform treatment protocols.
• Evaluate safety profiles by examining risk ratios for grade ≥3 adverse events like hypertension and hand-foot syndrome associated with TKI use.

Strengths

• Includes data from 10 randomized controlled trials, a standard for high-quality clinical evidence.
• Synthesizes outcomes for 1,810 total patients (1,169 experimental, 641 control), providing a substantial sample for meta-analysis.
• Reports effect sizes with 95% confidence intervals (CIs) for key endpoints like OS, PFS, ORR, and DCR.
• Assesses study quality using the Cochrane Risk of Bias 2 tool and evidence certainty using the GRADE framework.

Limitations

• The underlying data is a statistical summary (meta-analysis) of trial results, not raw patient-level data.
• The dataset is a single 335.2 KB DOCX file, limiting direct computational analysis without text extraction.
• Evidence certainty for some outcomes, like PFS and ORR, was graded as 'low' by the authors.

Provenance

Source

Systematic review and meta-analysis conducted by author Yongshan Li, sourced from figshare.

Collection Method

Data extracted from 10 RCTs identified via systematic search of PubMed, Web of Science, and Embase, following PRISMA 2020 guidelines.

Time Range

Literature search covered articles published up to March 1, 2026; specific trial dates not provided.

Freshness

Last updated March 24, 2026, with literature search current up to March 1, 2026.